AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Ellinas Finance Public Company LTD

Report Publication Announcement Oct 31, 2014

2465_iss_2014-10-31_924864ff-07f8-408c-aea0-23266b48e23d.pdf

Report Publication Announcement

Open in Viewer

Opens in native device viewer

October 30, 2014

Cyprus Stock Exchange Nicosia

ANNOUNCEMENT

Subject: Investment to NIPD Genetics Ltd from Ellinas Finance Public Company Limited

Ellinas Finance Public Company Limited («ELF») under the applicable law and for the sake of transparency and in order to fully inform ELF shareholders and the investing public, announces that the Board of Directors of ELF as its meeting held today, October 30, 2014, has decided to invest an amount of €200,250 by purchasing shares in the share capital of NIPD Genetics Ltd. This investment was identified in the process to locate new promising investment opportunities that aims to better diversify and ensure high yields.

NIPD Genetics Ltd was established in October 2010 with the primary objective to design, develop and manufacture products for the non-invasive prenatal diagnosis of Down Syndrome (Trisomy 21) and other genetic diseases. The company is under research and development stage for the development of the first commercial product. Therefore there are no major sources of income at the time and it is currently recording losses. It is expected that in 2015 NIPD will complete a comprehensive clinical validation study of eight hundred samples for determining the performance characteristics of NIPD tests for the detection of Down Syndrome.

The test for the non-invasive diagnosis of Down Syndrome will be the first product to be provided by NIPD Genetics Ltd. It is an important milestone for the company, as it will demonstrate that NIPD Genetics Ltd can develop and implement innovations on research level, into successful commercial applications and more realistically, will be the first source of significant revenues for the company. The market for prenatal diagnosis is enormous and it is estimated that in the developed world the market amounts to 2 billion dollars. It is predicted that the global market will reach 3.6 billion dollars by 2019.

The transaction was at arm's length.

Sincerely,

Constantinos Servos, Compliance officer

CC. Cyprus Securities and Exchange Commission

Talk to a Data Expert

Have a question? We'll get back to you promptly.